Johnson & Johnson (JNJ) just reported quarterly earnings and sales ahead of expectations, supported by both its Innovative Medicines and MedTech segments, while raising 2026 guidance and extending its dividend growth streak to 64 years.

Despite the earnings beat and steady dividend record, the stock is trading at US$226.71, with the share price down 5.01% over 30 days and 6.88% over 90 days. The 1-year total shareholder return of 53.99% and 5-year total shareholder return of 52.71% suggest that long term holders have seen materially different results from recent short term softness.

If J&J’s mix of established cash flows and new product launches has your attention, it can be useful to see which other healthcare companies are drawing interest for their use of AI in care delivery and diagnostics, starting with 32 healthcare AI stocks

So with earnings and guidance ahead of expectations, a 64 year dividend growth streak, and the share price easing in recent months, is Johnson & Johnson offering value today or is the market already pricing in its future growth?

Most Popular Narrative: 30.6% Overvalued

According to Goran_Damchevski, the most followed valuation narrative puts Johnson & Johnson’s fair value at $174 per share, well below the last close at $226.71. This frames the recent share price weakness in a different light.

Extending my 22x PE estimate to 2029, with a net income estimate of $24B, I get a future value of $528B, around $230 per share for JNJ.

Discounting back to today using Simply Wall St’s 5.8% rate, I get a new present value of $174 per share, which is $5 higher than my prior valuation estimate.

Want to see what kind of revenue growth, margin profile, and valuation multiple are baked into that fair value figure, and how they reshape the post Kenvue story?

Result: Fair Value of $174 (OVERVALUED)

However, this hinges on assumptions around litigation outcomes and patent expiries. Larger than expected settlements or faster competition could quickly challenge that fair value story.

Another View: DCF Points in the Opposite Direction

Goran’s narrative using earnings and multiples sees Johnson & Johnson as 30.6% overvalued at $226.71 versus a fair value of $174. Yet our DCF model, using future cash flows, suggests a value of $374.05, or 39.4% above the current price. Which set of assumptions resonates more with you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Johnson & Johnson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on valuation and sentiment, it helps to move quickly, review the underlying data, and weigh both sides of the story for yourself, starting with 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you only stop at Johnson & Johnson, you could miss other opportunities that fit your goals just as well, or even better, based on solid fundamentals.

• Target reliable income streams by comparing high yielding companies across 12 dividend fortresses and see which ones line up with your risk comfort.
• Spot potential bargains early by scanning companies that look mispriced on quality and fundamentals using the 49 high quality undervalued stocks before the crowd catches on.
• Prioritise capital preservation by focusing on companies highlighted in the 66 resilient stocks with low risk scores and build a watchlist that keeps volatility in check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.